News

NEW YORK, NY, April 17, 2023 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordinary share.

NEW YORK , NY,  April 13, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, March 27, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that the company’s Board of Directors has authorized the repurchase of up to $1.0 billion of the company’s Class A ordinary shares.

NEW YORK, NY, and BOSTON, MA, March 23, 2023 - Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry, and PureTech Health plc

NEW YORK, NY, March 15, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret (zavegepant)

NEW YORK, NY, March 1, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman.

NEW YORK, NY, February 15, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2022 and introduced full year 2023 guidance for Adjusted Cash Receipts(1) (non-GAAP financial measure).

NEW YORK , NY,  February 09, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and March: SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m.

NEW YORK, NY, January 18, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at

NEW YORK, NY, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company’s quarterly dividend over the previous quarter’s dividend.